A prognostic CpG score derived from epigenome-wide profiling of tumor tissue was independently associated with colorectal cancer survival

[1]  Alexander V. Favorov,et al.  Discovery and development of differentially methylated regions in human papillomavirus‐related oropharyngeal squamous cell carcinoma , 2018, International journal of cancer.

[2]  L. Kristensen,et al.  DNA Methylation Levels of the ELMO Gene Promoter CpG Islands in Human Glioblastomas , 2018, International journal of molecular sciences.

[3]  H. Brenner,et al.  Genome-wide DNA methylation analysis reveals a prognostic classifier for non-metastatic colorectal cancer (ProMCol classifier) , 2017, Gut.

[4]  A. Jemal,et al.  Colorectal cancer statistics, 2017 , 2017, CA: a cancer journal for clinicians.

[5]  M. Kloor,et al.  No association of CpG island methylator phenotype and colorectal cancer survival: population-based study , 2016, British Journal of Cancer.

[6]  H. Brenner,et al.  Different definitions of CpG island methylator phenotype and outcomes of colorectal cancer: a systematic review , 2016, Clinical Epigenetics.

[7]  W. Quint,et al.  CADM1 and MAL methylation status in cervical scrapes is representative of the most severe underlying lesion in women with multiple cervical biopsies , 2016, International journal of cancer.

[8]  M. Kloor,et al.  Statin use and survival after colorectal cancer: the importance of comprehensive confounder adjustment. , 2015, Journal of the National Cancer Institute.

[9]  T. Kuopio,et al.  Combination of microsatellite instability and BRAF mutation status for subtyping colorectal cancer , 2015, British Journal of Cancer.

[10]  S. Baylin,et al.  Prognostic value of CpG island methylator phenotype among colorectal cancer patients: a systematic review and meta-analysis. , 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

[11]  C. Plass,et al.  Pan-cancer patterns of DNA methylation , 2014, Genome Medicine.

[12]  I. Nagtegaal,et al.  Mismatch Repair Status and BRAF Mutation Status in Metastatic Colorectal Cancer Patients: A Pooled Analysis of the CAIRO, CAIRO2, COIN, and FOCUS Studies , 2014, Clinical Cancer Research.

[13]  Y. Oda,et al.  A CpG island methylator phenotype of colorectal cancer that is contiguous with conventional adenomas, but not serrated polyps , 2014, Oncology letters.

[14]  Jun S. Song,et al.  Recurrent epimutations activate gene body promoters in primary glioblastoma , 2014, Genome research.

[15]  Christian Stock,et al.  Reduced risk of colorectal cancer up to 10 years after screening, surveillance, or diagnostic colonoscopy. , 2014, Gastroenterology.

[16]  N. Cho,et al.  Prognostic implication of the CpG island methylator phenotype in colorectal cancers depends on tumour location , 2013, British Journal of Cancer.

[17]  V. Govorun,et al.  Genome-scale analysis of DNA methylation in colorectal cancer using Infinium HumanMethylation450 BeadChips , 2013, Epigenetics.

[18]  S. Varma,et al.  Toward a comprehensive and systematic methylome signature in colorectal cancers , 2013, Epigenetics.

[19]  Matty P Weijenberg,et al.  CHFR Promoter Methylation Indicates Poor Prognosis in Stage II Microsatellite Stable Colorectal Cancer , 2013, Clinical Cancer Research.

[20]  Ruth Pidsley,et al.  A data-driven approach to preprocessing Illumina 450K methylation array data , 2013, BMC Genomics.

[21]  T. Jin,et al.  Association between Gαi2 and ELMO1/Dock180 connects chemokine signalling with Rac activation and metastasis , 2013, Nature Communications.

[22]  Peter A. Jones.  Functions of DNA methylation: islands, start sites, gene bodies and beyond , 2012, Nature Reviews Genetics.

[23]  M. Esteller,et al.  Validation of a DNA methylation microarray for 450,000 CpG sites in the human genome , 2011, Epigenetics.

[24]  M. Kloor,et al.  Genetics and epigenetics of small bowel adenocarcinoma: the interactions of CIN, MSI, and CIMP , 2011, Modern Pathology.

[25]  Yu Zhou,et al.  CADM1/TSLC1 inactivation by promoter hypermethylation is a frequent event in colorectal carcinogenesis and correlates with late stages of the disease , 2011, International journal of cancer.

[26]  E. Dogliotti,et al.  Microsatellite instability as a marker of prognosis and response to therapy: a meta-analysis of colorectal cancer survival data. , 2010, European journal of cancer.

[27]  H. Aburatani,et al.  Three DNA Methylation Epigenotypes in Human Colorectal Cancer , 2009, Clinical Cancer Research.

[28]  Dong Sun Kim,et al.  Aberrant methylation of ADAMTS1 in non-small cell lung cancer. , 2008, Cancer genetics and cytogenetics.

[29]  Shuji Ogino,et al.  CpG island methylator phenotype, microsatellite instability, BRAF mutation and clinical outcome in colon cancer , 2008, Gut.

[30]  A. Lièvre,et al.  KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[31]  R. Nishikawa,et al.  ELMO1 and Dock180, a bipartite Rac1 guanine nucleotide exchange factor, promote human glioma cell invasion. , 2007, Cancer research.

[32]  G. Deng,et al.  Epigenetic changes (aberrant DNA methylation) in colorectal neoplasia. , 2007, Gut and liver.

[33]  M. Loda,et al.  Evaluation of markers for CpG island methylator phenotype (CIMP) in colorectal cancer by a large population-based sample. , 2007, The Journal of molecular diagnostics : JMD.

[34]  R. Lothe,et al.  ADAMTS1, CRABP1, and NR3C1 Identified as Epigenetically Deregulated Genes in Colorectal Tumorigenesis , 2006, Cellular oncology : the official journal of the International Society for Cellular Oncology.

[35]  P. Laird,et al.  CpG island methylator phenotype underlies sporadic microsatellite instability and is tightly associated with BRAF mutation in colorectal cancer , 2006, Nature Genetics.

[36]  A. Lièvre,et al.  KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer. , 2006, Cancer research.

[37]  M. Kloor,et al.  T25 repeat in the 3' untranslated region of the CASP2 gene: a sensitive and specific marker for microsatellite instability in colorectal cancer. , 2005, Cancer Research.

[38]  R. Penzel,et al.  Mutational activation of the RAS‐RAF‐MAPK and the wnt pathway in small intestinal adenocarcinomas , 2004, Scandinavian journal of gastroenterology.

[39]  J. Herman,et al.  Gene silencing in cancer in association with promoter hypermethylation. , 2003, The New England journal of medicine.

[40]  H. Fukuhara,et al.  Promoter methylation of the TSLC1 gene in advanced lung tumors and various cancer cell lines , 2003, International journal of cancer.

[41]  Hironori Katoh,et al.  RhoG activates Rac1 by direct interaction with the Dock180-binding protein Elmo , 2003, Nature.

[42]  J. Herman,et al.  CpG island methylator phenotype in colorectal cancer. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[43]  H. Brenner,et al.  Common genetic variation and survival after colorectal cancer diagnosis: a genome-wide analysis. , 2016, Carcinogenesis.

[44]  Hilde van der Togt,et al.  Publisher's Note , 2003, J. Netw. Comput. Appl..